SEC Form 4 · accession 0001505148-17-000014
PSYCHEMEDICS CORP · PMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred J Weinert
Director
Period of report
May 4, 2017
Accepted (ET)
May 5, 2017 · 4:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000806517
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.005 Par ValueF1,F2 | May 4, 2017 | A | 1,000 | $0.00 | A | 27,983 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $18.87 | May 4, 2017 | A | 10,000 | A | — | May 4, 2027 | Common Stock, $.005 Par Value | 10,000 | 10,000 | D |
Explanation of responses
- F1Represents restricted stock units that are to be settled solely in shares of Common Stock. The units vest with respect to 50% of the shares on April 30, 2018 and with respect to the remaining 50% on April 30, 2019, so long as the recipient continues as a director of the Issuer through each such respective vesting date.
- F2The reporting person also holds 108,381 shares indirectly by Trust and 200 shares by Spouse.
- F3The option becomes exercisable with respect to 50% of the shares on April 30, 2018 and with respect to the remaining 50% on April 30, 2019, so long as the recipient continues as a director of the Issuer through each such respective vesting date.